Literature DB >> 9492156

Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50.

G M Venkataraman1, M Yatin, K B Ain.   

Abstract

Elucidation of the regulation of human sodium-iodide symporter (hNIS) gene expression is critical to understanding its effects on iodide concentration abilities of thyroid and thyroid carcinomas. To explore this issue, a 1.2-kb portion of the 5'-flanking region of the hNIS gene was isolated and characterized. Transient transfections with chimeric luciferase-reporter constructs into a differentiated human thyroid cell line, KAT-50, as well as non-thyroidal cells, defined an active promoter with tissue-specificity. Reverse-transcriptase polymerase chain reaction analysis for hNIS mRNA expression in normal human tissues was positive in thyroid, salivary gland, omentum, and gallbladder. KAT-50 cells expressed hNIS mRNA and were capable of thyrotropin-responsive iodide uptake in vitro. Despite the failure to exhibit iodide concentration in clinical anaplastic carcinoma tumors, 4 of 5 cell lines from this cancer phenotype expressed hNIS mRNA. Definition of the active promoter provides further insights and tools to uncover new approaches to use of radioiodine for therapy of thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492156     DOI: 10.1089/thy.1998.8.63

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

Review 1.  Regulation of sodium/iodide symporter.

Authors:  S M Jhiang
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

4.  Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.

Authors:  W Xia; D Li; G Wang; J Ni; J Zhuang; M Ha; J Wang; Y Ye
Journal:  Cancer Gene Ther       Date:  2016-09-09       Impact factor: 5.987

5.  Expression of sodium iodide symporter in benign and malignant human thyroid tissues.

Authors:  J D Lin; C Hsueh; T C Chao; H F Weng
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells.

Authors:  Monica Dentice; Cristina Luongo; Antonia Elefante; Romina Romino; Raffaele Ambrosio; Mario Vitale; Guido Rossi; Gianfranco Fenzi; Domenico Salvatore
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 7.  Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.

Authors:  June-Key Chung; Hye Won Youn; Joo Hyun Kang; Ho Young Lee; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

8.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

9.  The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation.

Authors:  Hani Alotaibi; Merve Tuzlakoğlu-Öztürk; Uygar Halis Tazebay
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

10.  Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma.

Authors:  Qian Li; Bin Xu; Yunxiang Tang; Yuxia Li; Hong Ying
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.